Cardiff Oncology (NASDAQ:CRDF) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Cardiff Oncology (NASDAQ:CRDF) from a sell rating to a hold rating in a report released on Wednesday morning.

Several other equities analysts have also weighed in on CRDF. Piper Sandler reduced their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Noble Financial initiated coverage on shares of Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cardiff Oncology in a report on Wednesday, January 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.10.

Cardiff Oncology Stock Up 4.8%

CRDF stock opened at $1.98 on Wednesday. The firm has a market cap of $135.35 million, a PE ratio of -2.87 and a beta of 1.32. The business has a 50 day moving average of $2.26 and a 200-day moving average of $2.24. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.56.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.07. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%. On average, research analysts expect that Cardiff Oncology will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Cardiff Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Capital Advisors Wealth Management LLC bought a new position in shares of Cardiff Oncology in the fourth quarter valued at approximately $30,000. Tamar Securities LLC bought a new position in Cardiff Oncology in the 4th quarter valued at $32,000. Jeppson Wealth Management LLC bought a new position in Cardiff Oncology in the 3rd quarter valued at $25,000. Brooklyn Investment Group bought a new position in shares of Cardiff Oncology in the third quarter worth $26,000. Finally, R Squared Ltd bought a new position in shares of Cardiff Oncology in the fourth quarter worth $36,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.